Filing Flows › Schrodinger (SDGR) › Drug discovery revenue
Schrodinger (SDGR) Drug discovery revenue by quarter
Schrodinger's Drug discovery revenue was $24.2M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 5 quarters it ranged from $14.2M (Q2 2025) to $24.2M (Q3 2026).
| Quarter | Drug discovery revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $24.2M | +5% | — |
| Q2 2026 | $23.0M | +0.5% | +62% |
| Q1 2026 | $22.9M | +27% | — |
| Q4 2025 | $18.0M | +26% | — |
| Q2 2025 | $14.2M | — | — |
Q3 2026 at a glance
Schrodinger, Q3 2026: revenue $64.5M (+19% year over year), operating margin -40.5%, net loss $37.7M, operating cash flow −$47.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Schrodinger's Drug discovery revenue?
Schrodinger's Drug discovery revenue was $24.2M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Schrodinger's Drug discovery revenue changed?
Over the last 5 quarters it ranged from $14.2M (Q2 2025) to $24.2M (Q3 2026).